-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$45.20220.57% Upside
Rocket Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Rocket Pharmaceuticals, Inc.?
Rocket Pharmaceuticals, Inc. has been rated by research analysts at Canaccord Genuity, Morgan Stanley, Goldman Sachs, Raymond James, UBS in the past 90 days.